Federal Judge Halts North Dakota Law Mandating Drugmaker Discounts for Third-Party Dispensers

If you’ve walked into a pharmacy in Fargo or Bismarck lately, you’ve probably noticed the same thing: the price of insulin, inhalers, and even basic antibiotics hasn’t budged, despite promises from lawmakers that help was on the way. That sticker shock isn’t just bad luck—it’s the direct result of a federal judge’s decision this week to block North Dakota’s HB 1473, a law designed to force drug manufacturers to extend discounts to hospitals and clinics serving low-income patients. The ruling doesn’t just ripple across the state’s vast prairie; it sends a chilling message to cities like Minneapolis, where safety-net hospitals and community health centers have been counting on similar reforms to keep their doors open. And if you’re one of the thousands of Minnesotans who rely on the federal 340B drug discount program—whether you know it or not—this legal setback could mean higher copays, longer drives to the pharmacy, or even delayed care.

Here’s the crux of the issue: the 340B program, created by Congress in 1992, requires drug manufacturers to sell medications at steep discounts to hospitals and clinics that serve a disproportionate number of low-income or uninsured patients. In theory, these savings should trickle down to patients, reducing out-of-pocket costs for everything from HIV medications to cancer treatments. But in practice, drug companies have spent years erecting barriers—refusing to ship discounted drugs to contract pharmacies, imposing arbitrary limits on how many prescriptions a hospital can fill, or even cutting off entire networks of pharmacies from the program. North Dakota’s HB 1473 was supposed to be a fix. The law made it a misdemeanor for manufacturers to “deny, restrict, prohibit, or otherwise interfere” with pharmacies’ ability to dispense 340B-discounted drugs. It was a bold move, and one that other states—including Minnesota—had been watching closely.

That’s why Judge Dan Traynor’s ruling this week stings so much. In a 28-page decision, Traynor sided with pharmaceutical companies like Pfizer, Merck, and Eli Lilly, arguing that North Dakota’s law was “preempted” by the federal 340B statute. In other words, the state overstepped its authority by trying to regulate how drugmakers interact with pharmacies, a domain the judge said is already governed by federal law. The ruling doesn’t just halt the law in its tracks; it sets a precedent that could embolden drug companies to tighten their restrictions even further, leaving hospitals and patients with fewer options. For a state like Minnesota, where rural health clinics and urban safety-net hospitals rely on 340B savings to fund everything from free vaccines to mobile health vans, the implications are stark.

Take Hennepin Healthcare in Minneapolis, for example. The system serves more than 100,000 patients annually, many of whom are uninsured or on Medicaid. In 2025, Hennepin used 340B savings to fund a free clinic in the Phillips neighborhood, where diabetes and hypertension rates are among the highest in the state. But last year, several drug manufacturers stopped shipping discounted medications to Hennepin’s contract pharmacies, forcing the system to either absorb the cost or pass it on to patients. “We were already operating on razor-thin margins,” said a spokesperson for the system in a statement last fall. “When manufacturers cut off our access to 340B drugs, it’s not just a financial hit—it’s a threat to the care we can provide.”

The legal battle in North Dakota isn’t just about one state’s law; it’s a microcosm of a national fight over who should bear the burden of America’s sky-high drug prices. On one side, you have hospitals, clinics, and patient advocacy groups arguing that drug manufacturers are exploiting loopholes in the 340B program to pad their profits. On the other, pharmaceutical companies claim they’re being forced to subsidize a system that’s grown bloated and ripe for abuse. The industry’s trade group, PhRMA, has been particularly vocal, arguing that some hospitals and pharmacies have turned 340B into a “profit center” by reselling discounted drugs at full price to insured patients. “The 340B program was never intended to be a slush fund for hospitals,” a PhRMA spokesperson said in a statement last year. “It was meant to help vulnerable patients, and that’s where the focus should be.”

But patient advocates say the industry’s arguments are a smokescreen. “This isn’t about abuse—it’s about access,” said Sarah Chaffee, a policy analyst with the Minnesota-based nonprofit Health Access Minnesota. “When drug companies cut off discounts to pharmacies, they’re not punishing hospitals. They’re punishing patients who can’t afford their medications.” Chaffee points to data from the Minnesota Department of Health, which found that in 2024, nearly 1 in 5 Minnesotans skipped a prescription due to cost. For communities of color, the numbers are even worse: 28% of Black Minnesotans and 24% of Hispanic Minnesotans reported not filling a prescription because of the price. “These aren’t just statistics,” Chaffee said. “These are people who are rationing insulin, skipping blood pressure meds, or choosing between groceries and their prescriptions. And when manufacturers restrict 340B, they’re making that choice even harder.”

The fallout from Judge Traynor’s ruling is already being felt in unexpected places. In Moorhead, a city of 45,000 that straddles the Minnesota-North Dakota border, Essentia Health operates a network of clinics that serve patients from both states. Essentia has been vocal about the challenges of navigating 340B restrictions, particularly for patients who cross state lines for care. “A patient might live in Fargo but see a specialist in Moorhead, or vice versa,” said Dr. Lisa Jensen, Essentia’s chief medical officer. “When drug companies impose arbitrary limits on where we can fill prescriptions, it creates chaos for patients who are just trying to acquire the care they require.” Jensen said Essentia has had to hire additional staff just to navigate the patchwork of manufacturer restrictions, diverting resources away from patient care. “It’s like we’re playing a game of whack-a-mole with drug companies,” she said. “We fix one problem, and they discover another way to cut us off.”

For Minnesota lawmakers, the ruling in North Dakota is a wake-up call. State Representative Liz Olson, who represents Duluth and has been a vocal advocate for 340B reform, said the decision underscores the need for federal action. “States can’t do this alone,” Olson said in an interview last week. “We need Congress to step in and clarify the rules so that drug companies can’t keep playing games with patients’ lives.” Olson is part of a bipartisan group of lawmakers pushing for the 340B Integrity Act, a federal bill that would prohibit manufacturers from imposing restrictions on contract pharmacies. The bill has stalled in Congress for years, but Olson said the North Dakota ruling could give it novel momentum. “This isn’t a partisan issue,” she said. “It’s about whether we believe that low-income patients deserve access to affordable medications. And if we do, then we need to act.”

The legal battle isn’t over yet. North Dakota’s attorney general has already signaled plans to appeal Judge Traynor’s decision, and patient advocacy groups are mobilizing to support the state’s case. But for now, the ruling stands as a major victory for the pharmaceutical industry—and a setback for the hospitals, clinics, and patients who rely on 340B discounts to stay afloat. In Minnesota, where the cost of healthcare is already a top concern for voters, the decision is likely to fuel calls for state-level reforms. But with the legal landscape shifting, any new laws will have to be carefully crafted to avoid the same fate as North Dakota’s HB 1473.

So what does this mean for you, especially if you live in the Twin Cities or one of Minnesota’s rural communities? For starters, don’t expect your prescription costs to drop anytime soon. If you’re insured, you might see higher copays or deductibles as hospitals and clinics scramble to make up for lost 340B savings. If you’re uninsured or underinsured, the impact could be even more severe: longer wait times at safety-net clinics, fewer options for specialty medications, or even closures of rural health centers that can’t afford to operate without the discounts. And if you’re one of the thousands of Minnesotans who rely on a contract pharmacy—whether it’s a CVS in St. Paul or a local independent pharmacy in Mankato—you might find that your usual medications are suddenly harder to get.

But You’ll see steps you can take to protect yourself. First, if you’re prescribed a medication that’s suddenly unavailable or unaffordable, ask your doctor or pharmacist if there’s a generic alternative or a patient assistance program that can help. Many drug manufacturers offer coupons or discounts for low-income patients, though these programs often come with strings attached. Second, if you’re uninsured or struggling to afford your medications, glance into Minnesota’s Minnesota Rx Connect program, which provides free or low-cost prescriptions to eligible residents. And finally, if you’re concerned about the broader implications of the 340B ruling, consider reaching out to your elected officials. Groups like Health Access Minnesota and the Minnesota Hospital Association are pushing for state and federal reforms, and they need public support to make it happen.

What This Ruling Means for Minnesota’s Healthcare Ecosystem

The 340B program isn’t just a line item in a hospital’s budget—it’s a lifeline for Minnesota’s healthcare infrastructure. In 2025, the state’s 340B-covered entities saved an estimated $120 million through the program, with the majority of those savings reinvested in patient care. Those funds help pay for everything from free clinics in North Minneapolis to mobile health units that serve migrant farmworkers in the southern part of the state. When drug manufacturers restrict access to 340B discounts, those services are the first to go. “It’s not just about the money,” said Dr. Mark Sannes, an infectious disease specialist at Hennepin Healthcare. “It’s about the people who rely on us for care. When we lose 340B savings, we have to make hard choices about who we can serve, and how.”

One of the most vulnerable groups is Minnesota’s Native American population. The Indian Health Service (IHS) and tribal health clinics are among the largest participants in the 340B program, using the savings to fund everything from diabetes management programs to opioid addiction treatment. In 2024, the White Earth Nation’s health system used 340B savings to launch a mobile clinic that travels to remote reservations, providing primary care and mental health services to communities that might otherwise go without. But last year, several drug manufacturers stopped shipping discounted medications to the tribe’s contract pharmacies, forcing the system to scale back its services. “We’re talking about communities where the nearest hospital is 60 miles away,” said Dr. Sarah Brokenleg, the medical director of the White Earth Health Center. “When drug companies cut off our access to 340B, they’re not just hurting our budget—they’re putting lives at risk.”

The ruling also has implications for Minnesota’s rural hospitals, many of which are already on the brink of closure. According to the Minnesota Department of Health, 15 rural hospitals in the state have closed or converted to critical access status since 2010, largely due to financial pressures. For these hospitals, 340B savings can mean the difference between staying open and shutting their doors. In Fergus Falls, a city of 14,000 near the North Dakota border, Lake Region Healthcare has used 340B savings to fund a free clinic for uninsured patients. But in 2025, the hospital lost access to discounted medications from several manufacturers, forcing it to reduce the clinic’s hours and cut back on services. “We’re not a big urban hospital with deep pockets,” said Dr. John Halfen, Lake Region’s CEO. “When we lose 340B savings, we have to make cuts, and those cuts hurt the people who need us most.”

How to Navigate the Fallout: A Local Resource Guide

Given my background in healthcare policy and my work with organizations like Health Access Minnesota, I’ve seen firsthand how legal and regulatory changes can disrupt access to care. If this ruling impacts you or your community, here are the three types of local professionals Consider consider connecting with—and exactly what to look for when hiring them.

Healthcare Policy Attorneys

These are the lawyers who specialize in the intersection of healthcare and state/federal law. They can help hospitals, clinics, and patient advocacy groups navigate the legal fallout from the 340B ruling and explore alternative strategies for securing drug discounts. When hiring one, look for:

• Experience with 340B litigation: Ask if they’ve worked on cases involving the 340B program, particularly those related to manufacturer restrictions or state-level reforms. A background in Medicaid or Medicare law is also a plus.
• Knowledge of Minnesota’s healthcare landscape: The best attorneys will understand the unique challenges facing Minnesota’s hospitals and clinics, from rural access issues to the needs of urban safety-net providers. Ask if they’ve worked with organizations like the Minnesota Hospital Association or the Minnesota Medical Association.
• A track record of advocacy: Some healthcare policy attorneys focus on compliance, while others specialize in advocacy. If you’re a patient or a community group looking to push for reform, seek out an attorney with experience lobbying state legislators or filing amicus briefs in federal cases.

Pharmacy Benefit Consultants

These consultants help hospitals, clinics, and pharmacies optimize their drug purchasing strategies, including navigating the complexities of the 340B program. They can advise on everything from contract pharmacy arrangements to compliance with manufacturer restrictions. When hiring one, look for:

• Certification in 340B compliance: The best consultants will have certifications from organizations like the 340B Health or the American Pharmacists Association. Ask if they’ve completed the 340B University program, which is offered by the Health Resources and Services Administration (HRSA).
• Experience with Minnesota’s healthcare providers: Minnesota has a unique mix of large health systems (like Mayo Clinic and Allina Health) and small rural clinics. Look for a consultant who has worked with both, as their strategies for securing drug discounts may differ.
• A focus on patient outcomes: Some consultants prioritize cost savings over patient access, which can lead to short-sighted decisions. Ask for examples of how their work has improved access to medications for low-income or uninsured patients.

Community Health Advocates

These are the grassroots organizers, patient navigators, and nonprofit leaders who work directly with communities to improve access to care. They can help patients understand their rights, connect them with financial assistance programs, and advocate for policy changes at the local and state levels. When hiring one, look for:

• Deep ties to the community: The best advocates will have strong relationships with the populations they serve, whether that’s low-income families in the Twin Cities, Native American communities in northern Minnesota, or immigrant populations in Rochester. Ask how they engage with these communities and what feedback they’ve received.
• Experience with prescription assistance programs: Many advocates specialize in helping patients access free or low-cost medications through programs like Minnesota Rx Connect or manufacturer coupons. Ask if they’ve worked with these programs and how they help patients navigate the application process.
• A track record of policy wins: Some advocates focus on direct services, while others work to change the systems that create barriers to care. If you’re looking for someone to help push for state-level reforms, ask about their experience lobbying legislators, organizing rallies, or testifying at public hearings.

Navigating the fallout from the 340B ruling won’t be easy, but you don’t have to do it alone. Whether you’re a patient struggling to afford your medications, a healthcare provider trying to keep your clinic open, or a community leader fighting for policy change, there are local professionals who can help. The key is to find someone who understands the unique challenges facing Minnesota’s healthcare system—and who’s committed to putting patients first.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare policy experts in the Minnesota area today.